Literature DB >> 11162654

Antibodies against IFN gamma-binding proteins recognize a member of IFN alpha R complex.

I Bello1, L Rodes, P L Saura.   

Abstract

Recombinant human IFN alpha 2b coupled to a silica support was used for the purification of the IFN alpha-binding proteins from placental cell membrane extracts. The 100-kDa (p100) and 64-kDa (p64) proteins, which bind preferentially to an IFN alpha 2b-silica matrix, were identified. Using a monoclonal antibody (A6) against IFN-gammaR1, it was able to isolate p100 and p70, but only if IFN alpha 2b was present during chromatography. Similar interactions were observed using polyclonal antibody anti-IFN gamma binding proteins, as assayed in Western blot. These interactions were identified as conformation dependent. We speculate that IFN alpha 2b receptor complex shares an IFN gamma receptor complex epitope. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162654     DOI: 10.1006/bbrc.2000.4198

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

Authors:  Yanelda García-Vega; Idrian García-García; Sonia E Collazo-Caballero; Egla E Santely-Pravia; Alieski Cruz-Ramírez; Angela D Tuero-Iglesias; Cristian Alfonso-Alvarado; Mileidys Cabrera-Placeres; Nailet Castro-Basart; Yaquelín Duncan-Roberts; Tania I Carballo-Treto; Josanne Soto-Matos; Yoandy Izquierdo-Toledo; Dania Vázquez-Blomquist; Elizeth García-Iglesias; Iraldo Bello-Rivero
Journal:  BMC Pharmacol Toxicol       Date:  2012-12-28       Impact factor: 2.483

2.  Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.

Authors:  Idrian García-García; Ignacio Hernández-González; Alina Díaz-Machado; Carlos A González-Delgado; Sonia Pérez-Rodríguez; Yanelda García-Vega; Rosario Campos-Mojena; Ángela D Tuero-Iglesias; Carmen M Valenzuela-Silva; Alieski Cruz-Ramírez; Alis Martín-Trujillo; Héctor Santana-Milián; Pedro A López-Saura; Iraldo Bello-Rivero
Journal:  BMC Pharmacol Toxicol       Date:  2016-12-07       Impact factor: 2.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.